Cerebrolysin, hemorrhagic transformation, and anticoagulation timing after reperfusion therapy in stroke: post hoc secondary analysis of the CEREHETIS trial

In IVT-treated MCA stroke patients with HTI 1-4, Cerebrolysin may reduce HT hazard and advance the risk-equilibrium point by approximately 1-2 days. These findings are preliminary and hypothesis-generating, suggesting that Cerebrolysin may allow earlier-but individualized-anticoagulation resumption in selected high-risk patients, pending prospective validation.